ABBV Stock Chart & Fundamental Analysis

Interactive Chart

About AbbVie Inc.

Name

AbbVie Inc.

CEO

Robert A. Michael

Website

www.abbvie.com

Industry

Healthcare

Year Founded

2012

Employees

55,000

AbbVie Inc. (NYSE: ABBV) is a healthcare company that discovers, develops, manufactures, and commercializes advanced medicines across immunology, oncology, neuroscience, eye care, and other therapeutic areas around the world. In Drug Manufacturers - General, AbbVie generated $61.2 billion of revenue in FY2025.

Analyst Ratings

Consensus Recommendation

Buy5

Hold0

Sell2

Fundamentals & Financials

Revenue (TTM)

$62.8B

Net Income (TTM)

$3.6B

EPS (TTM)

$2.04

ROA (TTM)

2.67%

Current Ratio

0.8

Dividend Yield

0.8%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Item	Q1 FY2026	Q4 FY2025	Q3 FY2025
Revenue	$15,002M	$16,618M	$15,776M
Cost of Sales	$4,218M	$4,552M	$5,304M
Gross Profit	$10,784M	$12,066M	$10,472M
Operating Income	$4,734M	$5,809M	$1,904M
Net Income	$699,000K	$1,816M	$186,000K
EPS	$0.39	$1.02	$0.1

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings Calendar

Technical Indicators

AbbVie Inc.'s Technical Indicators Summary

AbbVie shows a strong technical posture driven by clear trend participation and broad moving-average support. The ADX indicates a competent trend, while momentum readings are mixed — MACD and CCI register bullish signals even as RSI and stochastics point to overbought conditions. Price sits well above short- and medium-term averages and also exceeds the 200‑day level, and on‑balance volume is positive, suggesting accumulation underneath recent strength. Volatility is moderate by ATR. Technical takeaway: Strong Buy — trend and volume support dominate despite overbought momentum.

Buy

5 signals

Neutral

0 signals

Sell

2 signals

Overall: Bullish71% Bullish signals

Indicator	Value	Signal	Explanation
RSI (14)	77.16	Sell	RSI (77.16) > 70, indicating overbought conditions.
Stochastic %K (14, 3, 3)	91.97	Sell	Stochastic (91.97) > 80, indicating overbought.
CCI (20)	151.68	Buy	CCI (151.68) > 100, indicating strong upward momentum.
WPR (14)	-1.23	Sell	Williams %R (-1.23) > -20, indicating overbought.
Momentum (10)	39.84	Buy	Momentum (39.84) is positive.
MFI	73.92	Neutral	MFI (73.92) is neutral.
MACD Level (12, 26)	10.37	Buy	Confirmed uptrend: MACD (10.37) is positive and above its signal line (7.56).
Bollinger Bands	$206.54 - $260.87	Sell	Price ($261.07) is above the upper band ($260.87).
ATR (14)	$6.71 (2.57%)	Neutral	Moderate Volatility (2.57%).
ADX (14)	29.79	Buy	Strong uptrend (ADX > 25) with bullish directional movement. ADX(29.79), +DI(42.44), -DI(12.13)
OBV	70,541,806	Buy	Bullish volume pressure: OBV is above its 20-day SMA. OBV(70,541,806), 20D-SMA-OBV(14,321,689)
Classic Pivot Point	$250.14	Buy	Price ($261.07) has broken above resistance R1 ($252.72) — bullish breakout potential.
Fibonacci Pivot Point	$250.14	Buy	Price ($261.07) has broken above resistance R1 ($251.76) — bullish breakout potential.
Exponential Moving Averages	$218.39 - $245.67(5 indicators)	Buy	EMA group: 5/5 bullish, 0 bearish, 0 neutral. Price above key EMA averages.
Simple Moving Averages	$218.52 - $243.07(5 indicators)	Buy	SMA group: 5/5 bullish, 0 bearish, 0 neutral. Price above key SMA averages.

Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.

Today's Snapshot

The day concluded with ABBV retaining the 3.98% gap it started with from yesterday. The session finished with relatively light trading in ABBV, at 0.39× its average volume. ABBV traded modestly on light volume as investors weigh its pipeline progress against Humira biosimilar risk and J&J competition.

Trading Volume

vs S&P 500 Today

Strong Outperformance

+10.31%

52-Week Position

Near highs

99.2%

Updated: July 2, 2026 at 20:07 UTC